The added value of 18 F-FDG PET/CT compared to 68 Ga-PSMA PET/CT in patients with castration-resistant prostate cancer

  • Chen R
  • Wang Y
  • Zhu Y
  • et al.
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Purpose: The 68Ga-PSMA PET/CT is a commonly used imaging modality in prostate cancers. However, few studies have compared the diagnostic efficiency between 68Ga-PSMA and 18F-FDG PET/CT and evaluated whether a heterogeneous metabolic phenotype (especially PSMA-FDG+ lesions) exists in patients with castration-resistant prostate cancer (CRPC). We determined the added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in CRPC patients and identified CRPC patients who may benefit from additional 18F-FDG PET/CT. Methods: Data of 56 patients with CRPC who underwent both 68Ga-PSMA and 18F-FDG PET/CT from May 2018 to February 2021 were retrospectively analysed. Patients were classified into two groups with or without PSMA-FDG+ lesions. The differences in patient characteristics between the two groups and predictors of patients who having at least one PSMA-FDG+ lesion were analysed. Results: Although both the detection rate (75.0% vs. 51.8%, P = 0.004) and positive lesion number (135 vs. 95) of 68Ga-PSMA PET/CT were higher than 18F-FDG PET/CT, there were still 13/56 (23.2%) patients with at least one PSMA-FDG+ lesion. The prostate-specific antigen (PSA) and Gleason score were both higher in the patients with PSMA-FDG+ lesions than in those without PSMA-FDG+ lesions ( P = 0.04 and P<0.001, respectively). Multivariate regression analysis showed that the Gleason score (≥8) and PSA (≥7.9 ng/mL) were associated with the detection rate of patients who had PSMA-FDG+ lesions ( P = 0.01 and P = 0.04, respectively). The incidences of having PSMA-FDG+ lesions in low-probability (Gleason score<8 and PSA<7.9 ng/mL), medium-probability (Gleason score≥8 and PSA<7.9 ng/mL or Gleason score<8 and PSA≥7.9 ng/mL), and high-probability (Gleason score≥8 and PSA≥7.9 ng/mL) groups were 0%, 21.7%, and 61.5%, respectively (P<0.001). Conclusion: Gleason score and PSA are significant predictors for PSMA-FDG+ lesions, and CRPC patients with high Gleason score and PSA may benefit from additional 18F-FDG PET/CT.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chen, R., Wang, Y., Zhu, Y., Shi, Y., Xu, L., Huang, G., & Liu, J. (2021). The added value of 18 F-FDG PET/CT compared to 68 Ga-PSMA PET/CT in patients with castration-resistant prostate cancer. Journal of Nuclear Medicine, jnumed.121.262250. https://doi.org/10.2967/jnumed.121.262250

Readers' Seniority

Tooltip

Researcher 3

60%

Professor / Associate Prof. 1

20%

PhD / Post grad / Masters / Doc 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

50%

Biochemistry, Genetics and Molecular Bi... 1

17%

Computer Science 1

17%

Arts and Humanities 1

17%

Save time finding and organizing research with Mendeley

Sign up for free